Cancer cell resistance to paclitaxel continues to be a major clinical problem. In this study, we utilized microRNA (miRNA) arrays to screen for differentially expressed miRNAs in paclitaxel-resistant cell lines established in vitro. We observed concordant upregulation of miR-135a in paclitaxel-resistant cell lines representing three human malignancies. Subsequently, the role of miRNA-135a was evaluated in an in vivo model of paclitaxel resistance. In this model, mice were inoculated subcutaneously with a non-small cell lung carcinoma cell line and treated with paclitaxel for a prolonged period. In paclitaxel-resistant cell lines, established either in vitro or in vivo, blockage of miR-135a sensitized resistant cell lines to paclitaxel-induced cell death. We further demonstrated a correlation between paclitaxel response and miR-135a expression in paclitaxel-resistant subclones that were established in vivo. The paclitaxel-resistant phenotype of these subclones was maintained upon retransplantation in new mice, as shown by decreased tumor response upon paclitaxel treatment compared with controls. Upregulation of miR-135a was associated with reduced expression of the adenomatous polyposis coli gene (APC). APC knockdown increased paclitaxel resistance in parental cell lines. Our results indicate that paclitaxel resistance is associated with upregulation of miR-135a, both in vitro and in vivo, and is in part determined by miR-135a-mediated downregulation of APC.
Cancer cell resistance to paclitaxel continues to be a major clinical problem. In this study, we utilized microRNA (miRNA) arrays to screen for differentially expressed miRNAs in paclitaxel-resistant cell lines established in vitro. We observed concordant upregulation of miR-135a in paclitaxel-resistant cell lines representing three human malignancies. Subsequently, the role of miRNA-135a was evaluated in an in vivo model of paclitaxel resistance. In this model, mice were inoculated subcutaneously with a non-small cell lung carcinoma cell line and treated with paclitaxel for a prolonged period. In paclitaxel-resistant cell lines, established either in vitro or in vivo, blockage of miR-135a sensitized resistant cell lines to paclitaxel-induced cell death. We further demonstrated a correlation between paclitaxel response and miR-135a expression in paclitaxel-resistant subclones that were established in vivo. The paclitaxel-resistant phenotype of these subclones was maintained upon retransplantation in new mice, as shown by decreased tumor response upon paclitaxel treatment compared with controls. Upregulation of miR-135a was associated with reduced expression of the adenomatous polyposis coli gene (APC). APC knockdown increased paclitaxel resistance in parental cell lines. Our results indicate that paclitaxel resistance is associated with upregulation of miR-135a, both in vitro and in vivo, and is in part determined byIntroduction Taxanes, such as paclitaxel and docetaxel, exert their cytotoxic effect through interaction with tubulin subunits, the building blocks of microtubules. Microtubules, formed by polymerization of heterodimeric a-and b-tubulin subunits, have fundamental roles in a wide range of cellular processes, such as maintenance of cell shape, cell signaling and cell division (Gelfand and Bershadsky, 1991) . By stabilizing microtubules and inhibiting their disassembly to tubulin, taxanes interfere with proper formation of the mitotic spindle, which leads to activation of the mitotic spindle checkpoint and mitotic arrest (Schiff et al., 1979) . Drug-treated cells eventually escape mitotic arrest without assembling a normal mitotic spindle. Depending on the cell type and concentration of taxanes used, these cells will undergo apoptosis during mitotic arrest or as a result of the abnormal mitosis (Shi et al., 2008) . The mechanisms of taxane-induced apoptosis are poorly understood, but involve both phosphorylation of Bcl-2 and activation of caspases-3 and -9 (Haldar et al., 1996; Perkins et al., 1998) .
Since the original US Food and Drug Administration (FDA) approval of paclitaxel for clinical use in advanced ovarian cancer in 1992, significant activity has been demonstrated against a broad spectrum of solid malignancies. At present, taxanes, used either as single agents or in combination with multiple other anticancer agents, are routinely used in the adjuvant, neoadjuvant and metastatic setting for a wide range of solid malignancies, including those of the breast, prostate, ovary, lung, head and neck (Dombernowsky et al., 1996; Chu et al., 2005; Mackler and Pienta, 2005; Wakelee et al., 2005) . Despite their widespread use, the clinical effectiveness of taxanes is limited by the emergence of taxane-resistant cancer cells, which ultimately leads to relapse and poor prognosis. Various mechanisms have been implicated in acquired or secondary taxane resistance. The best-studied mechanism is the upregulation of P-glycoprotein and related drug efflux pumps (Greenberger et al., 1988; Oguri et al., 2008) . Other mechanisms may involve inadequate interaction with spindle microtubules due to posttranslational modification or altered expression of tubulin and microtubule-associated proteins (Mozzetti et al., 2005; Villeneuve et al., 2006; McGrogan et al., 2008) or functional aberrations in molecular pathways, such as cell cycle control, the spindle assembly checkpoint and apoptosis (Anand et al., 2003; Sudo et al., 2004; McGrogan et al., 2008; Patel et al., 2010) . The contribution of each of these mechanisms to clinical resistance remains uncertain (Patel et al., 2010) .
MicroRNAs (miRNAs) are a class of small nonprotein coding RNAs that negatively modulate expression of cognate mRNAs (He and Hannon, 2004) . They act by targeting the RNA-induced silencing complex to complementary sites within the 3 0 -untranslated region (UTR) of their target mRNAs. Depending on the degree of base pairing between the miRNA and the 3 0 -UTR, either degradation or translational repression of the targeted mRNA will occur. Although they account for less than 1% of all human genes, miRNAs have been estimated to regulate up to 30% of all protein-encoding genes (Xie et al., 2005) . Altered miRNA expression has been observed in various human malignancies (Iorio et al., 2005; Esquela-Kerscher and Slack, 2006) . Surprisingly, miRNA expression profiles can predict tumor type and stage in human cancers with a better accuracy than the classical mRNA expression profiles . The significant correlation between miRNA expression patterns and compound potency in the NCI-60 panel of cell lines suggested that miRNAs have a role in chemoresistance (Blower et al., 2007) . Indeed, particular miRNAs have been shown to be involved in tumor responsiveness to chemotherapies, including paclitaxel (Kovalchuk et al., 2008; Sorrentino et al., 2008; Xia et al., 2008; Cochrane et al., 2009; Fujita et al., 2010; Zhou et al., 2010) . All studies to date have been performed in in vitro-established paclitaxel-resistant cell lines. Although these studies have provided valuable insight into the mechanisms of paclitaxel resistance, the clinical implication is uncertain.
In the present study, we have utilized miRNA arrays to identify miRNAs associated with the development of paclitaxel resistance in a panel of cell lines representing various human solid malignancies, which were made paclitaxel-resistant in vitro. Subsequently, the in vivo significance of the most discriminating miRNA was evaluated in a mouse model of paclitaxel resistance.
Results miRNA-135a is upregulated in various paclitaxelresistant cell lines A screen to identify miRNAs involved in paclitaxel resistance was performed in four cell lines that were made paclitaxel-resistant by continuous exposure to paclitaxel in vitro. We identified 18 miRNAs to be dysregulated at least twofold in paclitaxel resistant, compared with paclitaxel-sensitive parental cells (Supplementary Figure S1) . Supervised hierarchical clustering using the 18 differentially expressed miRNAs clustered cell lines according to cancer type rather than paclitaxel response ( Figure 1 ). As miR-135a was most highly and concordantly upregulated in more than one paclitaxel-resistant cell line, that is, 6.4-fold in PC-14 TXT cells and 9.1-fold in MES-SA DX5 cells, we further investigated the role of miR-135a in paclitaxel resistance. Quantitative real-time polymerase chain reaction (qRT-PCR) examination of miR-135a levels revealed a 1.5-fold upregulation in PC-14 TXT cells (P ¼ 0.029) and a 28-fold upregulation in MES-SA DX5 cells (Po0.001), confirming our miRNA array results (Figure 2 ). In addition, we observed upregulation of miR-135a in two other paclitaxel-resistant cell lines, that is, 2-fold in A549 TR (P ¼ 0.016) cells and 9.2-fold in SKOV TR cells (P ¼ 0.029), indicating that the association between miR-135a and paclitaxel resistance is not cell line specific (Figure 2 ). In contrast, cell survival was reduced to 62.7% when the same cells were transfected with an miR-135a inhibitor and then treated with paclitaxel ( Figure 3a , P ¼ 0.003). A similar result was obtained with A549 TR cells (Figure 3a) , where transfection with miR-135 inhibitor resulted in a trend towards increased cell sensitivity (P ¼ 0.054). To complement these studies, we elevated miR-135a levels in parental, paclitaxel-sensitive cells, with the expectation that this treatment would result in acquisition of the resistant phenotype. In this experiment (Figure 3b) , only 21.8% cell survival was observed in the MES-SA cells after treatment with 100 nM paclitaxel for 72 h. In contrast, 43.6% of the cells survived paclitaxel treatment after transfection with an miR-135a mimic. Again, as shown in Figure 3b TR were transfected with a scrambled non-targeting miRNA (control) and an miR-135a inhibitor (inhibitor), respectively, and the paclitaxel-sensitive parental MES-SA and A549 cells with a scrambled non-targeting miRNA (control) and an miR-135a mimic (mimic), respectively. Cells were subsequently treated with 100 nM paclitaxel and cell viability was assessed using the MTT assay (a, b). The % of apoptotic cells was assessed by Annexin V-staining and FACS analysis (c, d). Values are presented as % cell survival in paclitaxel-treated cells relative to untreated cells. *Po0.05, **Po0.001 as determined by Wilcoxon's rank sum test.
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A Holleman et al miR-135a (Nagel et al., 2008) . We confirmed that miR135a targeted the 3 0 -UTR of APC in both A549 ( Figure 4a ) and MES-SA cells (Figure 4b , P ¼ 0.029). To further explore the role of miR-135a upregulation in paclitaxel resistance, we examined APC expression in paclitaxelsensitive and -resistant cell lines. Analysis of APC mRNA expression levels revealed a 2.6-fold downregulation in A549 TR cells (Po0.001) and a 7-fold downregulation in MES-SA DX5 cells (Figure 4c , Po0.001). A concordant downregulation of APC was also observed at the protein level ( Figure 4c ). Transfection with the anti-miR-135a inhibitor restored APC expression, both at the mRNA ( Figure 4d ) and protein level (Figure 4e ).
miR-135a-induced paclitaxel resistance is partly mediated by APC downregulation
To test the role of APC in the cellular response to paclitaxel, APC expression was suppressed in parental A549 and MES-SA cells. Transfection with siRNA against APC completely suppressed APC expression in both cell lines ( Figure 5a ) and led to a decrease in paclitaxel-induced cytotoxicity in both cell lines (Figures 5b and c) . Similar results were obtained in A549 cells stably expressing short hairpin RNA against APC (Figures 5d and e) . These results suggest that downregulation of APC may be partly responsible for the effects of miR-135a on paclitaxel sensitivity in these cell lines. TR cells were mock-transfected, transfected with a scrambled miRNA (control inhibitor) or with a miR-135a inhibitor. Cells were fixed with paraformaldehyde, permeabilized and stained with APC-specific polyclonal antibodies, followed by fluorophoreconjugated secondary antibodies; nuclei were stained with DAPI. In addition, cells were lysed and APC protein levels were examined by western blot (bottom panel).
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The generation of paclitaxel-resistant cell lines in vivo To further establish the role of miR-135a in paclitaxel resistance, we adapted the A549 xenograft mouse model previously utilized in our laboratory (Patel et al., 2010) . Briefly, nude mice bearing subcutaneous A549 xenografts were injected intraperitoneally with either vehicle or 15 mg/kg paclitaxel, until tumors that responded initially started to regrow (Figure 6a ). Representative tumor growth curves are shown in Figure 6b . Vehicletreated tumors show rapid progressive growth (green lines). Paclitaxel-treated tumors show two general types of response: 7 out of 10 mice showed prolonged response (blue lines) and 3 out of 10 mice became paclitaxel-refractory, as demonstrated by an increase in tumor volume after initial volume reduction during continued treatment (red lines). After 120 days of paclitaxel treatment, control and paclitaxel-refractory tumors were harvested. Within two passages in vitro, RNA was harvested for miRNA evaluation and determination of paclitaxel response. Flow cytometric analysis demonstrated that the harvested cells were composed solely of human A549 cells, with no contaminating mouse cells (Supplementary Figure S3) . Cell lines established from paclitaxel-refractory tumors (black bars) were more resistant to paclitaxel in vitro than either parental A549 cells (white bars) or vehicletreated tumors (striped bars, Figure 6c ). Treatment of xenotransplanted mice with 10 and 12.5 mg/kg paclitaxel did not generate any paclitaxel-refractory tumors (Supplementary Figure S4) .
Cells selected for paclitaxel resistance remain resistant upon retransplantation Tumor clone 20.2 (T20.2), the most paclitaxel-resistant tumor in the series, was transplanted into 20 syngeneic mice. Half of these animals were treated with vehicle and half were subjected to another round of intraperitoneal treatment with 15 mg/kg paclitaxel. Tumor clone 28.2 served as a sensitive control in this experiment because: (1) it has an LC 50 value for paclitaxel that is similar to the parental A549 cells; (2) it is paclitaxel-naive; and (3) it is similar to T20.2, as both were previously grown in mice. As shown in Figure 7a , xenografts established from T20.2 showed only a slight delay in tumor growth 
A Holleman et al when tested with paclitaxel, whereas xenografts established from the paclitaxel-sensitive control T28.2 shrank substantially upon paclitaxel treatment. At the end of the experiment, the relative tumor burden was reduced 4.5-fold in paclitaxel-sensitive control cells (P ¼ 0.003), but only 1.4-fold in mice bearing T20.2 xenografts (Figure 7b ). The decreased paclitaxel response of T20.2 compared with T28.2 in mice was associated with a decreased paclitaxel response in vitro (Figure 7c , P ¼ 0.01). The maintenance of paclitaxel resistance upon retransplantation suggests that paclitaxel resistance is associated with stable changes in the tumor rather than in transient changes induced by exposure to the host environment.
miR-135a is upregulated in in vivo paclitaxel resistance In our in vitro experiments, we established a role for miR-135a in the cellular response to paclitaxel. To explore the role of miR-135a expression in vivo, we examined miR-135a expression in three cell lines representing various degrees of paclitaxel resistance. Paclitaxel resistance increased gradually from a median LC 50 value of 1.14 nM in the parental A549 cells to 13.27 nM after one in vivo passage (P ¼ 0.030) and to 126.6 nM after re-injection (P ¼ 0.008, Figure 8a ). As shown in Figure 8b , decreased paclitaxel response is significantly associated with increased miR-135a expression in tumors selected for paclitaxel resistance in vivo. Cells have a median 1.9-fold higher expression after the initial in vivo passage (round 1) and a 4.1-fold higher expression of miR-135a, compared with the parental A549 cells (P ¼ 0.004). The correlation between miR135a expression and paclitaxel response was observed in all cell lines derived from these tumors (Figure 8c , Po0.001). Transfection with an miR-135a inhibitor modestly increased paclitaxel-induced cytotoxicity in paclitaxel-resistant cells (Figure 8d ). Furthermore, transfection of an miR-135a mimic suppressed paclitaxel-induced cytotoxicity in paclitaxel-sensitive cells (Figure 8e ). Together, these results show that miR135a is involved in the paclitaxel sensitivity of the cell lines established after long-term exposure to paclitaxel in vivo.
miR-135a modulates tumor response to paclitaxel in vivo We subsequently investigated the role of miR-135a in paclitaxel sensitivity in vivo. To this aim, A549 cells stably expressing miR-135a were generated, which (Figure 9a ). As expected, miR-135a knockdown attenuated paclitaxel-induced cell death (Figure 9b ) and APC protein expression (Figure 9c ) relative to control transfected A549 cells in vitro. If overexpression of miR-135a is causally involved in paclitaxel-resistance in vivo, tumors artificially overexpressing miR-135a should show decreased paclitaxel sensitivity. To investigate this hypothesis, A549 control cells and A549 cells stably overexpressing an miR-135a mimic were inoculated subcutaneously into the flanks of nude mice. Paclitaxel treatment was given three times a week for 3 weeks, and tumor size in each group was monitored during the course of treatment. At the end of the experiment, the relative tumor burden was reduced 5-fold in A549 control cells (Po0.001). A549 cells overexpressing miR-135a showed increased cell growth in vivo relative to control untreated cells. In vivo growth of miR-135a overexpressing cells was not reduced by paclitaxel exposure (Figure 9d ). This result demonstrates that miR-135a overexpression alone induces taxane resistance that is maintained during tumor growth in vivo.
Discussion
Despite their widespread use, the clinical effectiveness of taxanes is limited by the emergence of taxane-resistant cancer cells. Our current knowledge of the mechanisms underlying paclitaxel resistance is largely derived from in vitro models, where resistance is induced by repeated or prolonged exposure of cultured cells to gradually increasing drug concentrations. Although this methodology has imparted important knowledge, it has potential disadvantages. First, cells in solid tumors in vivo tend to be more drug resistant than the same cells grown in a monolayer in vitro (Hoffman, 1991; Kobayashi et al., 1993) . This can be explained by various factors including decreased drug penetration, quiescence of cells in deeper layers due to cell contact inhibition and hypoxia, or resistance arising from an adaptive, reciprocal signaling between tumor cells and the surrounding microenvironment (Pollard, 2004; Meads et al., 2009) . Second, treatment in culture bears little resemblance to in vivo pharmacokinetics and does not allow the formation of active metabolites that may be produced by metabolic activity. Third, the in vitro situation does not address the role of the tumor microenvironment in the generation of drug resistance. To confirm the role of miRNA-135a in paclitaxel resistance, we established a new in vivo mouse model of paclitaxel resistance.
One way to circumvent this problem is to use mice that develop spontaneous tumors as a consequence of conditional tissue-specific mutations in proto-oncogenes and tumor suppressor genes. Using this approach, Rottenberg et al. (2007) 
generated docetaxel-resistant Brca1
À/À ;p53 À/À mammary tumors. In that study, tumors that responded to paclitaxel were allowed to grow back to their original size before treatment was resumed. We employed a different approach to the in vivo selection of paclitaxel-resistant tumors. In our model, mice were inoculated with paclitaxel-sensitive tumor cells and then treated with paclitaxel three times per week, consistent with current clinical practice.
Similar approaches have been employed by others to establish drug-resistant cell lines (Starling et al., 1990; Teicher et al., 1990; Okugawa et al., 2004) . Interestingly, contrary to our model, resistance was not maintained when the established cell lines were exposed to paclitaxel in vitro in these models. The authors suggested that drug resistance in in vivo established cell lines might be dependent on an miR-135a in paclitaxel resistance A Holleman et al interaction between the tumor and the host stromal tissues, rather than changes at the cellular level. The maintenance of drug resistance in vitro in our model could be explained by our selection method. Both Okugawa et al. (2004) and Teicher et al. (1990) retransplanted cells in a new recipient mouse after a single drug dose. This procedure was repeated six and ten times in a 6-month period, respectively. Mice of Starling et al. (1990) were treated seven times in 8 weeks, with a treatment-free interval of 3 weeks between the first and second rounds of treatment. In contrast, our three times per week schedule for 42 weeks is associated with a prolonged and continuous selective pressure. It has been proposed that acquired drug resistance arises in a step-wise fashion as a consequence of random mutations in tumor subclones (Goldie and Coldman, 1979) . Some of these mutations will, by chance, result in an increased survival in the presence of the drug being used, causing this subclone to be selected during therapy. Resistance at the cellular level, without the necessity of signals from the microenvironment, may occur at a later stage in the development of resistance, explaining the maintenance of paclitaxel resistance ex vivo in our model. As clinical paclitaxel resistance usually takes several months to develop, our model may represent a promising new paradigm to elucidate mechanisms of paclitaxel resistance. miR-135a is a member of the miR-135 subfamily, which is comprised of miR-135a and miR-135b. Our current work demonstrates that upregulation of miR-135a correlates with the acquisition of taxane resistance in cells selected for resistance either in vitro or in vivo. Manipulation of miR-135a levels has a functional effect on taxane sensitivity in these lines. Our results suggest that suppression of miR-135a may be a reasonable approach to improving or prolonging drug sensitivity.
A recent report showed that the tumor suppressor gene APC is targeted by the miR-135a family (Nagel et al., 2008) . In the present paper, we confirm that APC is an miR-135a target and suggest miR-135a-mediated APC downregulation as one possible mechanism for miR-135a-induced taxane resistance. The best-known function of the APC protein is the regulation of the Wnt signaling cascade through downregulation of b-catenin (Giles et al., 2003) . Loss of APC expression leads to nuclear accumulation of b-catenin and inappropriate activation of its target genes (Giles et al., 2003) , Figure 9 Overexpression of miR-135a confers paclitaxel resistance in A549 cells in vivo. A549 cells stably expressing either nontargeting premiR (A549-control) or premiR-135a (A549-miR-135a) were generated. (a) miR-135a expression level in A549-control and -miR-135a was determined and compared with A549 and A549 TR cells using qRT-PCR analysis. *Po0.01. (b) Paclitaxel response of A549-control and A549-premiR-135a cells was determined using the MTT assay. (c) APC protein expression was examined using western blot analysis in A549-control and -premiR-135a cells. (d) A549-control and -premiR-135a cells were inoculated subcutaneously into the flanks of nude mice. Paclitaxel treatment was given three times a week for 3 weeks. The tumor size in each group was measured during the course of treatment and was calculated, relative to the size before treatment initiation. Each curve represents the average tumor growth±s.e.m. for 10 mice per group. **Po0.001 as determined by Wilcoxon's rank sum test.
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A Holleman et al including the growth-promoting genes c-myc and cyclin-D1 and the anti-apoptotic gene survivin (Zhang et al., 2001) . Collectively, these changes can lead to reduced paclitaxel-induced apoptosis (Dikovskaya et al., 2007) . In addition, defects in the mitotic checkpoint function have been associated with reduced paclitaxel-induced apoptosis (Anand et al., 2003; Sudo et al., 2004) . APC regulates the mitotic checkpoint by binding to microtubules during mitosis (Fodde et al., 2001 ) and interacting with kinetochore-associated proteins (Kaplan et al., 2001; Aoki and Taketo, 2007) . Consequently, knockdown of APC by miR-135a may contribute to paclitaxel resistance by decreasing apoptosis, directly or indirectly by interfering with the mitotic spindle checkpoint.
Additional mechanisms for miR-135a induction of paclitaxel resistance are possible and merit future testing. A recent report showed that treatment with the angiogenesis inhibitor endostatin significantly improved the anti-tumor efficacy of paclitaxel in Lewis lung cell carcinoma (Huang and Chen, 2010) . This implicates increased angiogenesis in paclitaxel resistance. Hypoxia-inducible factor 1 (HIF-1) is the key regulator of oxygen homeostasis that controls angiogenesis, erythropoiesis and glycolysis through transcriptional activation of target genes under hypoxic conditions (Fong, 2008) . Hypoxia-inducible factor 1-alpha inhibitor (HIF1AN) is a protein that binds to HIF-1a and inhibits its transcriptional activity (Mahon et al., 2001) . HIF1AN is a potential miR-135a target listed in both the TargetScan and PicTar databases. Efforts to identify deregulation of other miR-135 targets in our model are currently being pursued in our laboratory, using a combination of genomic approaches and in silico analysis of previously published datasets.
The role in paclitaxel resistance that we propose here for miR-135a offers the intriguing possibility that clinical taxane resistance could be reversed by inhibiting miR-135a and/or its deregulated downstream pathways. The use of anti-miRs as a therapeutic tool was demonstrated in a recent study, where intratumoral injection of anti-miR-221/222 led to a reduction in tumor growth in a subcutaneous prostate cancer xenograft tumor model (Mercatelli et al., 2008) . Unfortunately, intratumoral injection is not feasible for the majority of cancers, and the success of systemic gene-based therapy has been limited to date by fundamental barriers to RNA delivery. Although new approaches to direct miRNA delivery are being widely investigated, non-gene-based approaches may be feasible as well. For example, several small-molecule antagonists capable of disrupting APC have been identified (Lepourcelet et al., 2004) and represent potential alternatives to genetic manipulation.
In conclusion, we demonstrate that miR-135a is involved in paclitaxel resistance, both in vitro and in vivo. In addition, we show that miR-135a-mediated paclitaxel resistance is, in part, mediated by downregulation of APC. Although the present paper is solely focused on miR-135a, this miRNA represents only one of the many possible miRNAs that are likely to be involved in paclitaxel resistance, as we found additional miRNAs to be upregulated in the initial screening of our cell lines. Our in vivo model represents a promising new paradigm to elucidate mechanisms of paclitaxel resistance. Future genomic or proteomic profiling of the paclitaxel-resistant cell clones generated in this model is likely to generate important new insights into the mechanisms of paclitaxel resistance.
Materials and methods

Cell lines
The human non-small cell lung cancer cell line A549 and its paclitaxel-resistant derivative cell lines were described previously (Patel et al., 2010) . The human non-small cell lung cancer cell line PC-14 and its docetaxel-resistant cell line PC-14/ TXT were provided by Dr Nagahiro Saijo (National Cancer Center Research Catherinenstitute, Tokyo, Japan), the human breast cancer cell line MCF-7 and the multidrug-resistant derivative MCF-7 TAX were provided by Dr Amadeo Parissenti (Laurentian University, Sudbury, Ontario, Canada) (Villeneuve et al., 2006) , the human prostate cancer cell line PC-3 and the paclitaxel resistant variant PC-3 TXR were provided by Dr Atsushi Mizokami (University of Kanazawa, Kanazawa, Japan) (Takeda et al., 2007) and the human ovarian cancer cell line SKOV-3 and the paclitaxel resistant variant SKOV-3 TR were provided by Dr Zhenfeng Duan (Massachusetts General Hospital, Boston, MA, USA). Multi-drug resistant human uterine sarcoma cells MES-SA DX5 were purchased from ATCC (Manassas, VA, USA). All cells were cultured at 37 1C in a humidified atmosphere, with 5% CO 2 in media supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Life Technologies, Carlsbad, CA, USA). Media and paclitaxel (Cytoskeleton, Denver, CO, USA) concentrations used are specified in Supplementary Figure S5. RNA purification, labeling and hybridization Cells were harvested in log-phase growth and total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol, with an additional extraction with phenol:chloroform:isoamyl alcohol 25:24:1. RNA integrity was assessed with an Agilent Bioanalyser 2100 (Agilent, Palo Alto, CA, USA). Total RNA of 2 mg was labeled using the miRCURYt Hy3t/Hy5t labeling kit and hybridized on the miRCURYt LNA Array v.11.0 (Exiqon, Vedbaek, Denmark), according to the manufacturer's protocol. A common reference pool was constructed using RNA from all samples. Hybridization of the Hy5-labeled pool to each array facilitates comparison of ratios across datasets (Yang and Speed, 2002) .
Processing of microarray data
Arrays were scanned using a laser confocal scanner (Agilent) and Hy3 (cell line) and Hy5 (common reference pool) signal intensities were calculated. Arrays were repeated if control oligonucleotides did not produce signals within the expected range. In successful arrays, signal intensities were background corrected using the normexp method (Ritchie et al., 2007) with offset value k ¼ 10 and normalized using the global Lowess (locally weighted scatterplot smoothing) regression algorithm (Cleveland, 1979) . The log2 median ratio (LMR) value was calculated per miRNA probe set by log2-transformation of the mean Hy3/Hy5 ratio. The DLMR value, that is, Figure S6) . Tumor size was determined by digital caliper measurements (length and width in mm), and tumor volume (mm 3 ) was estimated using the formula (length Â width 2 )/2. Effects on tumor growth rate were assessed per mouse by determining the tumor volume on the day of treatment, relative to the tumor volume on Day 0. Animals were killed, once morbidity became evident or their tumor size exceeded 1000 mm 3 . Following the indicated treatments, A549 tumors were removed, minced and expanded in vitro, without further exposure to paclitaxel, and stored in liquid nitrogen. All animal studies were conducted in accordance with the guidelines established by the internal Institutional Animal Care and Use Committee.
Cytotoxicity assays
Cell growth inhibition was determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT; Sigma Chemicals, St Louis, MO, USA) bromide assay. Briefly, B2.5 Â 10 4 cells were plated in a 96-well plate and paclitaxel was added in appropriate concentrations 24 h later. An equivalent amount of diluent (dimethyl sulfoxide) was added to culture medium as a negative control. After 72 h of drug incubation, 20 ml of MTT (Sigma Chemicals; 20 mg/ml) was added to each well. After incubation for an additional 4 h, 200 ml of isopropanol-HCl solution was added to each well to dissolve the cell pellets. Absorbance was determined using a 96-well SpectraMax plate reader (Molecular Devices, Sunnyvale, CA, USA) at 560 nm and 650 nm (background).
Quantitative real-time PCR (qRT-PCR)
Total cellular RNA was extracted using Trizol reagent (Invitrogen). In order to quantify APC mRNA expression levels, cDNA was synthesized using the iScript cDNA synthesis kit (Bio-Rad Laboratories, Richmond, VA, USA) and qRT-PCR was carried out using iQ SYBR Green master mix (Bio-Rad). Primer sequences used are: APC, 5 0 -GGAAG CAGAGAGAAAGTACTGGA-3 0 (sense) and 5 0 -CTGAAG TTGAGCGTAATACCAG-3 0 (antisense), GAPDH, 5 0 -GTA TTGGGCGCCTGGTCACC-3 0 (sense) and 5 0 -CGGGAA GATG GTGATGG-3 0 (antisense). Expression of miR-135a and 5S sRNA as a reference was analyzed by the mirVana qRT-PCR miRNA Detection Kit (Ambion/Applied Biosystems, Austin, TX, USA), in conjunction with RT-PCR with SYBR Green I (Bio-Rad). All reactions were conducted in triplicate in a LightCycler 480 Real-Time PCR System (Roche, Indianapolis, IN, USA). Gene expression was calculated relative to GAPDH (for APC) or 5S rRNA (for miR-135a) using the comparative cycle time (C t ) method.
Transfections and luciferase assay Double-stranded RNA oligos representing a mature sequence that mimics endogenous miR-135a, anti-miR-135a designed to inhibit endogenous miR-135a, and anti-miR negative control were all obtained from Ambion and were transfected into cell lines at B50% confluence at 30 nM concentration with siLentFect (Bio-Rad). For luciferase activity analysis, cells were seeded in 96-well plates and 100 ng Luc-APC-3 0 -UTR reporter vector (SwitchGear Genomics, Menlo Park, CA, USA) and 30 nM miR-135a mimic or 30 nM non-targeting control were cotransfected with Lipofectamine 2000 (Invitrogen). An empty vector containing random genomic fragments served as a negative control. The next day, luciferase activity was measured using the Dual-Glo Luciferase assay system (Promega, Madison, WI, USA). For siRNA-mediated APC knockdown, an siRNA against human APC and a scrambled non-targeting siRNA (ON-Target PLUS Smartpool, Dharmacon, Lafayette, CO, USA) were transfected with Dharmacon Transfection reagent I into A549 cells before analyzing for protein expression at 48 h post-transfection. For the paclitaxel dose response, cells were re-seeded 24 h after transfection and treated with paclitaxel the next day and harvested 48 h posttreatment using MTT assay. In generating A549 cells stably expressing miR-135a, expression plasmids for human miRNA135a and its non-targeting control (Origene, Rockville, MD, USA) were transfected using Lipofectamine 2000, before selection with 750 mg/ml Neomycin.
Annexin V assay
Annexin V/7-amino-actinomycin D labeling was performed according to the manufacturer's instructions (BD Pharmingen, San Diego, CA, USA, 559 763) and samples were analyzed by flow cytometry. Briefly, cells were treated for 48-72 h with either vehicle or 100 nM paclitaxel. Cells were trypsinized and washed with phosphate-buffered saline before resuspending in assay binding buffer. Annexin V and 7-amino-actinomycin labeling was performed at room temperature for 15 min before analysis by flow cytometry (BD FACScan, San Jose, CA, USA).
Western blot and immunocytochemical studies
Protein was extracted and the protein content was determined using the Bio-Rad Protein Assay Kit (Bio-Rad), with bovine serum albumin as the standard. Protein samples (50 mg) were fractionated by SDS-PAGE (7% polyacrylamide gels) and transferred to PVDF membrane (Millipore, Bedford, MA, USA). The samples were incubated overnight at 4 1C with a primary antibody directed against the C-terminus of APC (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Bound secondary horseradish peroxidase-conjugated antibodies were detected using the ECL detection system (Amersham/GE Healthcare, Pittsburgh, PA, USA). Immunofluorescence for APC was carried out on cells seeded on round glass coverslips coated with 10 mg/ml fibronectin (BD Biosciences) in 24-well plates. Before staining, cells were treated with 30 nM of miRNA inhibitor. At the end of treatment, cells were washed with ice-cold phosphate-buffered saline containing 1 mM MgCl 2 and 1 mM CaCl 2 . Cells were fixed with 3.7% formaldehyde (Sigma) for 15 min at room temperature and stained for APC (1:50) with the primary antibody for 1 h, followed by extensive washing and incubation with secondary antibody (Alexa 488-conjugated donkey anti-goat IgG, Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA, 1:1000) in the dark for 30 min.
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